Pharmaceutical Technology

DECEMBER 9, 2022

M&A – Commended PRODUCT LAUNCHES – Commended RESEARCH AND DEVELOPMENT – Commende d. Solvias is a Swiss-based pharmaceutical company focused on contract research, development and manufacturing. Pharmaceutical Technology Excellence Rankings – The Verdict.

Development 130

Development Production Manufacturing Vaccination 130

pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders. That muffles the immune system response and allows the cancer to grow.

DNA 52

DNA Immune Response Genome Genomics 52

XTalks

DECEMBER 1, 2021

Researchers say it will take a few weeks before more is known about the transmissibility, virulence (i.e., While researchers are still working out the epidemiological, clinical and molecular details of Omicron, so far, it is known that the variant is laden with up to 50 mutations, 30 or so of which are just in its outer spike (S) protein.

Gene 105

Gene Genome Genomics Genetics 105

Roots Analysis

MARCH 8, 2023

Over time, various research studies have demonstrated the potential of exosomes ( membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA.

RNA 52

RNA Drug Delivery DNA Development 52

The Pharma Data

JANUARY 31, 2021

Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

OCTOBER 25, 2020

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

The Pharma Data

OCTOBER 28, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., 29, 2020 06:00 UTC. CAMBRIDGE, Mass.–(

Vaccination 40

Vaccination Vaccine Manufacturing Clinical Trials 40

Drug Discovery World

AUGUST 3, 2022

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. These peptides typically contain up to 30 amino acids and can be cationic, amphipathic or both. These considerations limit their application as therapeutics.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Dec. million to 7.5

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

XTalks

AUGUST 18, 2023

Khanani, director of clinical research at Sierra Eye Associates, Reno, Nevada, in Iveric Bio’s news release. Izervay contains avacincaptad pegol sodium, an effective complement C5 inhibitor. Avacincaptad pegol combines an RNA aptamer with a roughly 43-kiloDalton (kDa) branched polyethylene glycol (PEG) molecule.

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

Pharmaceutical Technology

NOVEMBER 22, 2022

Devex’s global COVID-19 funding dashboard recorded $172 million invested in vaccine research between 1 January 2020 and 27 June 2020. According to CEPI: “Achieving the 100 Days Mission would give the world a fighting chance of containing a future outbreak before it spreads to become a global pandemic.”.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

The Pharma Data

AUGUST 30, 2021

As the first and only small interfering RNA to provide effective and sustained LDL-C reduction, Leqvio helps manage a critical cardiovascular risk factor for ASCVD. Leqvio is the first and only approved small interfering RNA (siRNA) LDL-C-lowering treatment in Europe 6,7. It is currently under review by the U.S. Disclaimer.

RNA 52

RNA Trials Production Containment 52

The Pharma Data

MARCH 5, 2021

This will be adapted to the needs of messenger RNA vaccine production for CureVac’s CVnCoV, the manufacturing of which is highly complex. At the Kundl site, Novartis is a pioneer and has decades of experience in pharmaceutical production of proteins and in more recent years of nucleic acids. Disclaimer. Source link:[link].

Manufacturing 52

Manufacturing Vaccination Vaccine Production 52

The Pharma Data

JULY 18, 2021

“Some adults, including older adults or those with certain chronic medical conditions or immunocompromising conditions, are at increased risk for pneumococcal disease and its serious, sometimes life-threatening complications,” said Dr. Jose Cardona, Indago Research and Health Center, coordinating investigator for the PNEU-AGE trial.

Immune Response 52

Immune Response Vaccination Vaccine FDA Approval 52

XTalks

AUGUST 10, 2021

The test was developed by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Massachusetts Institute of Technology (MIT) and several Boston area hospitals. The researchers published the details of the device in a paper in Science Advances. SHERLOCK Design: CRISPR COVID-19 Test.

RNA 105

RNA Containment DNA Engineer 105

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. 20, 2020 02:44 UTC. CAMBRIDGE, Mass.–(

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

The Pharma Data

JANUARY 10, 2021

Turkish researchers reported interim data on the same vaccine in December showing 91.25% efficacy. INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the Fc domain of the immunoglobulin IgG1. The drug is an RNA interference (RNAi) therapeutic. Non-COVID-19-Related.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

The Pharma Data

NOVEMBER 16, 2020

mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. BARDA is supporting the continued research and development of mRNA-1273 with $955 million in federal funding under Contract no.

Vaccination 52

Vaccination Vaccine Containment Pharmacy 52

Delveinsight

DECEMBER 13, 2020

Research and development in Hepatitis. However, there is still a need for further research on HCV and the risk factors that lead to the progression of fibrosis, cirrhosis, and Hepatocellular carcinoma (HCC). The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa).

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. CAMBRIDGE, Mass.–(BUSINESS

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pfizer

AUGUST 15, 2022

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. FDA Emergency Use Authorization Statement. 07.27.2022.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. The vaccine contains a small piece of the SARS-CoV-2 virus’s mRNA that instructs cells in the body to make the virus’s distinctive “spike” protein.

Vaccination 52

Vaccination Vaccine Production Manufacturing 52

The Pharma Data

SEPTEMBER 8, 2020

Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. Sanofi, Empowering Life.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. Defense Advanced Research Projects Agency.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Drug Discovery World

MAY 2, 2023

Some of the most important breakthroughs in pharmaceutical research were adapted from naturally occurring phenomena. Bacterial RNA is replaced by a synthetic guide RNA (gRNA) that can recognise a specific target DNA sequence. The gRNA is accompanied by the Cas9 enzyme responsible for cutting DNA.

Genome 52

Genome Genomics Gene DNA 52

XTalks

NOVEMBER 7, 2022

“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace. cfDNA Isolation Techniques.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Pfizer

JANUARY 27, 2023

Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.

Marketing 75

Marketing Production Drugs Licensing 75

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Roots Analysis

AUGUST 31, 2023

Further, the expression of any gene is dependent on the rate at which it is transcribed into mRNA and translated into proteins. There are various regulatory proteins or transcription factors that are responsible for affecting the transcription rate. These genetic switches assist transcription factors in binding to the promoter region.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Pharmaceutical Technology

FEBRUARY 1, 2023

Given the urgent need for new therapies, researchers have been largely focused on new mAb and vaccine development. As an RNA virus, like SARS-CoV-2, RSV is highly prone to mutations. However, specific antibody-resistant mutations have already been documented within the RSV- F protein after prophylactic administration of nirsevimab.

Vaccination 162

Vaccination Vaccine Antibody Protein 162

Drug Discovery World

AUGUST 10, 2022

But decades of research led to improvements in cancer therapy, centred around the idea that one’s immune system could aid in treatment. Their continued promise has led to an exponential increase in research on their utility, function, risks, and potential benefits. Developing the first CAR T cell therapy.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic. million and $38.8 million, respectively, as compared to $17.6

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

DECEMBER 26, 2023

Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance and prevent the spread of disease.

Development 64

Development Clinical Trials Clinical Trials Drugs 64

The Pharma Data

SEPTEMBER 1, 2020

COVID-19 testing solutions that provide healthcare professionals and patients with a quick answer regarding their infection status are critical to contain the community-spread of the COVID-19 virus. We are actively involved in understanding the potential of our existing portfolio and are researching options for the future.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

The Pharma Data

MARCH 20, 2021

Coronaviruses are RNA viruses and include common human coronaviruses, severe acute respiratory syndrome-CoV (SARS-CoV), Middle East respiratory syndrome-CoV (MERS-CoV) and SARS-CoV-2 ( 1 ). Nucleocapsid protein from SARS patients was abundant enough to be detected in clinical samples using an ELISA approach ( 20 ). INTRODUCTION.

Protein 52

Protein Antibody Development RNA 52